Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

Background Sipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We examined whether administering ipilimumab after sipuleucel-T could modify immune and/or clinical...

Full description

Bibliographic Details
Main Authors: Padmanee Sharma, Sumit Subudhi, James P Allison, Rahul Aggarwal, Eric J Small, Terence W Friedlander, Brandon Chen, Jaqueline Marquez, Kate Allaire, Alexander Cheung, Sharon Ng, Christopher Nguyen, Matthew Spitzer
Format: Article
Language:English
Published: BMJ Publishing Group 2021-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/5/e002254.full

Internet

https://jitc.bmj.com/content/9/5/e002254.full

Similar Items